Lapatinib: Vorinostat

Abstract

The increasing complexity of cancer chemotherapy increases the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy, and review various agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr., President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@aol.com; or J. Aubrey Waddell, Associate Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Get full access to this article

View all access options for this article.

References

Burris

3rd , Hurwitz

H.L.

, Dees

E.C.

. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005; 23: 5305–5313.

Harrington

K.J.

, Bourhis

, Nutting

C.M.

. A phase I, open-label study of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) [abstract 5553]. Proc Am Soc Clin Oncol. 2006 ASCO Annual Meeting. Available at: http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=40&abstractID=33944. Accessed March 23, 2007.

Ross

H.J.

, Blumenschein

G.R.

, Dowlati

, Aisner

, Rigas

J.R.

, Stanislaus

, Leopold

L.H.

Preliminary safety results of a phase II trial comparing two schedules of lapatinib (GW572016) as first line therapy for advanced or metastatic non-small cell lung cancer [abstract 7099]. Proc Am Soc Clin Oncol. 2005 ASCO Annual Meeting. Available at: http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=34&abstractID=33663. Accessed March 23, 2007.

Gomez

H.L.

, Chavez

M.A.

, Doval

D.C.

. Biomarker results from a phase II randomized study of lapatinib (GW572016) as first-line treatment for patients with ErbB2 FISH-amplified advanced or metastatic breast cancer [abstract 1071]. 28th Annual San Antonio Breast Cancer Symposium 2005. Available at: www.sabcs.org. Accessed February 20, 2006.

Dejonge

, Savage

, Verweij

. A phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently [abstract 3088]. Proc Am Soc Clin Oncol. 2006 ASCO Annual Meeting. Available at: http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=40&abstractID=34591. Accessed March 23, 2007.

Burris

H.A.

, Storniolo

A.M.

, Overmoyer

E.A.

. A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab [abstract 3043]. 29th Annual San Antonio Breast Cancer Symposium 2006. Available at: www.sabcs.org. Accessed February 20, 2006.

Lin

N.U.

, Carey

L.A.

, Liu

M.C.

. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer [abstract 503]. Proc Am Soc Clin Oncol. 2006 ASCO Annual Meeting. Available at: http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=40&abstractID=32820. Accessed March 23, 2007.

Midgley

, Flaherty

K.T.

, Haller

D.G.

. Phase I study of GW572016 (lapatinib), a dual kinase inhibitor, in combination with irinotecan (IR), 5-fluorouracil (FU) and leucovorin (LV) [abstract 3086]. Proc Am Soc Clin Oncol. 2005 Annual Meeting. Available at: http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&con-fID=34&abstractID=32687. Accessed March 23, 2007.

Fields

A.L.

, Rinaldi

D.A.

, Henderson

C.A.

. An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer [abstract 3583]. Proc Am Soc Clin Oncol. 2005 ASCO Annual Meeting. Available at: http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=34&abstractID=30589. Accessed March 23, 2007.

10.

Wülfing

, Machiels

, Richel

. A single arm, multicenter, open label, ph II study of lapatinib as 2L treatment of pts with locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract [abstract 4594]. Proc Am Soc Clin Oncol. 2005 ASCOAnnualMeeting. Available at: http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=34&abstractID=31739. Accessed March 23, 2007.

11.

Ravaud

, Gardner

, Hawkins

. Efficacy of lapatinib in patients with high tumor EGFR expression: Results of a phase III trial in advanced renal cell carcinoma (RCC) [abstract 4502]. Proc Am Soc Clin Oncol. 2006 ASCO Annual Meeting. Available at: http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=40&abstractID=33904. Accessed March 23, 2007.

12.

Chu

, Cianfrocca

M.E.

, Murray

. A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients [abstract 6044]. 29th Annual San Antonio Breast Cancer Symposium 2006. Available at: www.sabcs.org. Accessed March 23, 2007.

13.

Geyer

C.E.

, Forster

, Lindquist

. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. New Engl J Med. 2006; 355: 2733–2743.

14.

Spector

N.L.

, Blackwell

, Hurley

. EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): clinical activity and biologic predictors of response [abstract 502]. Proc Am Soc Clin Oncol. 2006 ASCO Annual Meeting. Available at: http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=40&abstractID=34006. Accessed March 23, 2007.

15.

Agulnik

, Cohen

E.E.

, Cohen

R.B.

. A phase II study of lapatinib in recurrent or metastatic EGFR and/or ErbB2 expressing adenoid cystic (ACC) and non-ACC malignant tumors of the salivary glands (MSGT) [abstract 5566]. Proc Am Soc Clin Oncol. 2006 ASCO Annual Meeting. Available at: http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=40&abstractID=31579. Accessed March 23, 2007.

16.

Jones

S.F.

, Burris

H.A.

, Yardley

D.A.

. Lapatinib (an oral dual kinase inhibitor) plus weekly or every 3 week paclitaxel [abstract 1069]. 2006. Available at: www.sabcs.org. Accessed March 23, 2007.

17.

Abidoye

O.O.

, Cohen

E.E.

, Wong

S.J.

. A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) [abstract 5568]. Proc Am Soc Clin Oncol. 2006 ASCO Annual Meeting. Available at: http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=40&abstractID=32889. Accessed March 23, 2007.

18.

Tykerb [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2007.

19.

Zolinza [package insert]. White-house Station, NJ: Merck & Co., Inc.; 2006.

20.

Kelly

W.K.

, O'Connor

O.A.

, Krug

L.M.

. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005; 23: 3923–3931.

21.

O'Connor

O.A.

, Heaney

M.L.

, Schwartz

. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 2006; 24: 166–173.

22.

Olsen

, Kim

Y.H.

, Kuzel

. Vorinostat (suberoylanilide hydroxamic acid, SAHA) is clinically active in advanced cutaneous T-cell lymphoma (CTCL): Results of a phase IIb trial [abstract 7500]. Proc Am Soc Clin Oncol. 2006 ASCO Annual Meeting Available at: http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=40&abstractID=30812. Accessed March 23, 2007.

23.

Duvic

, Talpur

, Ni

. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007; 109: 31–39.

24.

Garcia-Manero

, Yang

, Sanchez-Gonzalez

. Final results of a phase I study of the histone deacetylase inhibitor vorinostat (suberoyanilide hydroxamic acid, SAHA), in patients with leukemia and myelodysplastic syndrome [abstract 2801]. Proc Am Soc Hematol. 2005. Available at: www.hematology.org. Accessed March 23, 2007.

25.

Fakih

M.G.

, Pendyala

, Toth

, Creaven

, Soehnlein

, Litwin

, Trump

A phase I study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in patients with advanced colorectal cancer (CRC) [abstract 3592]. Proc Am Soc Clin Oncol. 2006 ASCO Annual Meeting. Available at: http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=40&abstractID=30652. Accessed March 23, 2007.

26.

Luu

, Morgan

R.J.

, Leong

. Vorinostat (suberoylanilide hydroxamic acid -SAHA) as salvage therapy in metastatic breast cancer (BC): a California cancer consortium phase II study [abstract 1109]. 29th Annual San Antonio Breast Cancer Symposium 2006. Available at: www.sabcs.org. Accessed March 23, 2007.

27.

Ramalingam

, Parise

R.A.

, Egorin

M.J.

. Phase I study of vorinostat, a histone deacetylase (HDAC) inhibitor, in combination with carboplatin (Cb) and paclitaxel (P) for patients with advanced solid malignancies (NCI #6922) [abstract 2077]. Proc Am Soc Clin Oncol. 2006 ASCO Annual Meeting. Available at: http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=40&abstractID=32058. Accessed March 23, 2007.